Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: Abrogation of S/G2 arrest

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 3, 2000, Pages 252-258

  Jones, Carleton B ^a   Clements, Mark K ^a   Wasi, Safia ^b   Daoud, Sayed S ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Breast cancer; Camptothecin; Cell cycle; Drug synergism; Endothelial cells; UCN 01

Indexed keywords

7 HYDROXYSTAUROSPORINE; CAMPTOTHECIN; PROTEIN KINASE C; PROTEIN P53; STAUROSPORINE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0000061105     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050037     Document Type: Article

References (38)

1. 1. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M (1991) Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in marine and human tumor models. Cancer Res 51: 4888
2. 2 phase arrest by different antitumor agents. Eur J Cancer 14: 741
3. 2-checkpoint inhibitor. Clin Cancer Res 2: 791
4. 4. Chou T-C, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27
5. 5. Dancey J, Eisenhauer EA (1996) Current perspectives on camptothecins in cancer treatment. Br J Cancer 74: 327
6. 6. D'Apra P, Beardmore C, Liu LF (1990) Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50: 6919
7. 7. Daoud SS, Forde NH (1991) Synergistic cytotoxic actions of cisplatin and liposomal valinomycin on human ovarian carcinoma cells. Cancer Chemother Pharmacol 28: 370
8. 8. Daoud SS, Juliano RL (1989) Modulation of doxorubicin resistance by valinomycin (NSC 122023) and liposomal valinomycin in Chinese hamster ovary cells. Cancer Res 49: 2661
9. 9. Darzynkiewicz Z, Bruno S, Del Bino G, Traganos F (1996) The cell cycle effects of camptothecins. In: Pantazis P, Giovanella BC, Rothenberg ML (eds) The camptothecins from discovery to the patient, vol 803. New York Academy of Sciences, New York, p 93
10. 10. Dubrez L, Goldwasser F, Genne P, Pommier Y, Solary E (1995) The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemia cells to topoisomerase I and II inhibitors. Leukemia 9: 1013
11. 11. Fan S, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Forance AJ, Magrath I, Kohn KW, O'Connor PM (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54: 5824
12. 12. Fan S, Smith LM, Rivett, JD, Duba D, Zhan Q, Kohn WK, Fornace JA, O'Connor MP (1995) Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649
13. 2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 56: 4430
14. 14. Jones CB, Clements MK, Wasi S, Daoud SS (1997) Sensitivity to camptothecin of human breast cancer cells and normal bovine endothelial cells, in vitro. Cancer Chemother Pharmacol 40: 475
15. 15. Jones CB, Clements MK, Wasi S, Daoud SS (1997) Synergy between UCN-01 and camptothecin-induced cytotoxicity in breast cancer cells. Proc Am Assoc Cancer Res 38: 102
16. 16. Hartwell LH, Weinert TA (1989) Checkpoints: controls that ensure the order of the cell cycle events. Science 246: 629
17. 17. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Graig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304
18. 18. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491
19. 19. Lane DP (1992) p53, guardian of the genome. Nature 358: 15
20. 20. Lee JM, Bernstein A (1993) p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 90: 5742
21. 21. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266: 807
22. 22. Lush RM, Senderowicz A, Figg WD, Headlee D, Inoue K, Sausville EA (1997) Surprising pharmacokinetics of UCN-01 in patients with refractory neoplasms may be due to high degree of protein binding. Proc Am Assoc Cancer Res 38: 4029
23. 23. Monks A, Vaigro-Wolf A, Hose C, Sausville EA, O'Connor PM (1997) Synergistic interactions between UCN-01 and various anti-cancer agents in vitro: relationship to p53 function. Proc Am Assoc Cancer Res 38: 2137
24. 24. O'Connor PM, Nieves-Neira W, Kerrigan D, Bertrand R, et al (1991) S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methyldioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Commun 3: 233
25. 25. Pines J (1995) Cyclins, cdks and cancer. Semin Cancer Biol 6: 63
26. 2 delay. Cancer Res 55: 1643
27. 27. Raibowol K, Draetta G, Brizuela L, Vandre D, Beach D (1989) The cdc2 kinase is a nuclear protein that is essential for mitosis in mammalian cells. Cell 57: 393
28. 1 checkpoint-deficient and competent cells. Cancer Res 55: 1639
29. 29. Ryan AJ, Squires S, Strutt HL, Johnson RT (1991) Camptothecin cytotoxicity in mammalian cells is associated with the interaction of persistent double strand breaks in replicating DNA. Nucleic Acids Res 19: 3295
30. 30. Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland JP (1993) Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 53: 2081
31. 31. Sinha BK (1995) Topoisomerase I inhibitors: a review of their therapeutic potential in cancer. Drugs 49: 11
32. 2 arrest and DNA double-strand breaks. Cancer Res 48: 4484
33. cdc2/cyclin B complex in vitro by human cdc25 protein. Nature 351: 242
34. 34. Takahashi I, Kobayashi E, Asano K, Yoshida M, Nakano H (1987) UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J Antibiot 40: 1782
35. cdc2/cyclin B. Cancer Res 52: 1823
36. 36. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA (1995) Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinase 1 and 2. Cell Growth Differ 6: 927
37. 2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88: 956
38. 38. Wang Y, Perrault AR, Iliakis G (1997) Down-regulation of DNA replication in extracts of camptothecin-treated cells: activation of an S-phase checkpoint. Cancer Res 57: 1654